Email this page: News Release

MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by MAP Pharmaceuticals, Inc. for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps MAP Pharmaceuticals, Inc. prevent automated submissions.